Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MYGN Myriad Genetics	$6.02 +3.3%	$5.15	$3.76 ▼ $29.30	$560.13M	1.89	2.48 million shs	1.01 million shs
RIGL Rigel Pharmaceuticals	$41.50 -1.2%	$24.11	$12.00 ▼ $43.72	$744.39M	1.21	808,428 shs	895,255 shs
ZBIO Zenas BioPharma	$17.10 +1.0%	$13.26	$5.83 ▼ $26.25	$720.08M	N/A	160,623 shs	231,632 shs
ZIOP ZIOPHARM Oncology		$1.08	$0.77 ▼ $5.95	$187.12M	1.71	2.01 million shs	2.13 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MYGN Myriad Genetics	+3.26%	+5.43%	+27.00%	+53.96%	-78.45%
RIGL Rigel Pharmaceuticals	-1.17%	+5.04%	+96.96%	+119.00%	+231.47%
ZBIO Zenas BioPharma	+1.00%	+1.66%	+9.48%	+49.61%	+1,709,999,900.00%
ZIOP ZIOPHARM Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MYGN Myriad Genetics	3.6247 of 5 stars	3.1	2.0	0.0	4.1	2.4	1.7	0.0
RIGL Rigel Pharmaceuticals	1.679 of 5 stars	1.2	1.0	0.0	0.0	2.6	1.7	3.1
ZBIO Zenas BioPharma	1.4764 of 5 stars	3.5	0.0	0.0	0.0	1.5	0.8	0.0
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MYGN Myriad Genetics	2.21	Hold	$12.45	106.89% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	-7.95% Downside
ZBIO Zenas BioPharma	3.00	Buy	$36.67	114.42% Upside
ZIOP ZIOPHARM Oncology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZIOP, RIGL, ZBIO, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MYGN Myriad Genetics	$837.60M	0.67	$1.00 per share	6.03	$4.17 per share	1.44
RIGL Rigel Pharmaceuticals	$179.28M	4.15	$1.08 per share	38.47	$4.57 per share	9.08
ZBIO Zenas BioPharma	$5M	144.02	N/A	N/A	$5.69 per share	3.01
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	11/6/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	7.67	39.52	N/A	36.51%	438.89%	57.03%	11/6/2025 (Estimated)
ZBIO Zenas BioPharma	-$156.99M	-$3.55	0.00	∞	N/A	N/A	-59.21%	-50.56%	11/11/2025 (Estimated)
ZIOP ZIOPHARM Oncology	-$79.98M	-$0.43	N/A	N/A	N/A	N/A	-92.84%	-72.46%	N/A

Latest ZIOP, RIGL, ZBIO, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	-$1.25	-$0.23	-$1.25	$5.00 million	N/A
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MYGN Myriad Genetics	N/A	1.42	1.28
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90
ZBIO Zenas BioPharma	N/A	5.23	5.23
ZIOP ZIOPHARM Oncology	0.18	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MYGN Myriad Genetics	99.02%
RIGL Rigel Pharmaceuticals	66.23%
ZBIO Zenas BioPharma	N/A
ZIOP ZIOPHARM Oncology	51.03%

Insider Ownership

Company	Insider Ownership
MYGN Myriad Genetics	2.40%
RIGL Rigel Pharmaceuticals	9.48%
ZBIO Zenas BioPharma	16.50%
ZIOP ZIOPHARM Oncology	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MYGN Myriad Genetics	2,700	93.04 million	90.81 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable
ZBIO Zenas BioPharma	N/A	42.11 million	35.16 million	N/A
ZIOP ZIOPHARM Oncology	105	216.15 million	204.91 million	Optionable

ZIOP, RIGL, ZBIO, and MYGN Headlines

Recent News About These Companies

TCRT stock touches 52-week low at $1.62 amid market challenges

January 30, 2025 | msn.com

Best Global Universities for Oncology

September 11, 2024 | usnews.com

FDA fast-tracks Merck's cancer blockbuster-in-waiting

July 28, 2024 | pharmaphorum.comP

BMS signs $475m cancer immunotherapy deal with Dragonfly

July 23, 2024 | pharmaphorum.comP

Childhood Cancers

February 17, 2024 | curetoday.comC

Alx Oncology Holdings (ALXO)

February 10, 2024 | investing.com

Pediatric Hematology-Oncology Fellowship

February 5, 2024 | bcm.eduB

Alaunos Therapeutics: Other Events, Financial Statements And Exhibits

January 31, 2024 | cbonds.comC

CG Oncology Inc

January 31, 2024 | reuters.com

Oncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients

December 21, 2023 | medscape.comM

Immuno-Oncology

December 19, 2023 | ajmc.comA

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?

December 18, 2023 | markets.businessinsider.com

Exploring Patient-Centered Handoffs in Surgical Oncology

December 10, 2023 | medscape.comM

Association of Community Cancer Centers

October 14, 2023 | ajmc.comA

Oncology News and Research

September 19, 2023 | news-medical.netN

WBSPH 2024 - Oncology

September 15, 2023 | newsweek.comN

Kris on Oncology

September 6, 2023 | medscape.comM

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

August 29, 2023 | thestreet.com

Oncology Cases & Quizzes

August 14, 2023 | medscape.comM

Ziopharm’s palifosfamide fails in first-line STS…

June 20, 2023 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIOP, RIGL, ZBIO, and MYGN Company Descriptions

Myriad Genetics NASDAQ:MYGN

$6.02 +0.19 (+3.26%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.00 -0.02 (-0.33%)

As of 08/22/2025 07:33 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Rigel Pharmaceuticals NASDAQ:RIGL

$41.50 -0.49 (-1.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$41.38 -0.13 (-0.30%)

As of 08/22/2025 07:52 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Zenas BioPharma NASDAQ:ZBIO

$17.10 +0.17 (+1.00%)

As of 08/22/2025 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time